nach oben

Acta Diabetologica

Erschienen in:

02.02.2021 | Review Article

Novel biomarkers of diabetic kidney disease: current status and potential clinical application

verfasst von: Federica Barutta, Stefania Bellini, Silvia Canepa, Marilena Durazzo, Gabriella Gruden

Erschienen in: Acta Diabetologica | Ausgabe 7/2021

Einloggen, um Zugang zu erhalten

Abstract

Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease (ESRD). Although both albuminuria and glomerular filtration rate (GFR) are well-established diagnostic/prognostic biomarkers of DKD, they have important limitations. There is, thus, increasing quest to find novel biomarkers to identify the disease in an early stage and to improve risk stratification. In this review, we will outline the major pitfalls of currently available markers, describe promising novel biomarkers, and discuss their potential clinical relevance. In particular, we will focus on the importance of recent advancements in multi-omic technologies in the discovery of new DKD biomarkers. In addition, we will provide an update on new emerging approaches to explore renal function and structure, using functional tests and imaging.

Alicic RZ, Rooney MT, Tuttle KR (2017) Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol 12:2032–2045. https://doi.org/10.2215/CJN.11491116CrossRefPubMedPubMedCentral

Penno G, Solini A, Bonora E et al (2011) Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. J Hypertens. https://doi.org/10.1097/HJH.0b013e3283495cd6CrossRefPubMed

Gonzalez Suarez ML, Thomas DB, Barisoni L, Fornoni A (2013) Diabetic nephropathy: is it time yet for routine kidney biopsy? World J Diabet 4:245–255. https://doi.org/10.4239/wjd.v4.i6.245CrossRef

Caramori ML (2017) Should all patients with diabetes have a kidney biopsy? Nephrol Dial Transplant 32:3–5. https://doi.org/10.1093/ndt/gfw389CrossRefPubMed

Alicic RZ, Rooney MT, Tuttle KR (2017) Diabetic kidney disease: challenges, progress, and possibilities. CJASN 12:2032–2045. https://doi.org/10.2215/CJN.11491116CrossRefPubMedPubMedCentral

Fioretto P, Mauer M (2007) Histopathology of diabetic nephropathy. Semin Nephrol 27:195–207. https://doi.org/10.1016/j.semnephrol.2007.01.012CrossRefPubMedPubMedCentral

MacIsaac RJ, Ekinci EI, Jerums G (2014) Progressive diabetic nephropathy. How useful is microalbuminuria?: contra. Kidney Int 86:50–57. https://doi.org/10.1038/ki.2014.98CrossRefPubMed

Angiano Gómez L, Lei Y, Devarapu SK, Anders HJ (2018) The diabetes pandemic suggests unmet needs for ‘CKD with diabetes’ in addition to ‘diabetic nephropathy’—implications for pre-clinical research and drug testing. Nephrol Dial Transplan 33:1292–1304. https://doi.org/10.1093/ndt/gfx219CrossRef

Anders HJ, Huber TB, Isermann B, Schiffer M (2018) CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol 14:361–377. https://doi.org/10.1038/s41581-018-0001-yCrossRefPubMed

10.

Tonneijck L, Muskiet MHA, Smits MM et al (2017) Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J Am Soc Nephrol 28:1023–1039. https://doi.org/10.1681/ASN.2016060666CrossRefPubMedPubMedCentral

11.

Niewczas MA, Gohda T, Skupien J et al. (2012) Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol 23:507–515. https://doi.org/10.1681/ASN.2011060627CrossRefPubMedPubMedCentral

12.

Pavkov ME, Nelson RG, Knowler WC, Cheng Y, Krolewski AS, Niewczas MA (2015) Elevation of circulating TNF receptors 1 and 2 increases the risk of end-stage renal disease in American Indians with type 2 diabetes. Kidney Int 87:812–819. https://doi.org/10.1038/ki.2014.330CrossRefPubMed

13.

Barr ELM, Barzi F, Hughes JT et al (2018) High baseline levels of tumor necrosis factor receptor 1 are associated with progression of kidney disease in indigenous Australians with diabetes: the eGFR follow-up study. Diabet Care 41:739–747. https://doi.org/10.2337/dc17-1919CrossRef

14.

Forsblom C, Moran J, Harjutsalo V et al (2014) Added value of soluble tumor necrosis factor-α receptor 1 as a biomarker of ESRD risk in patients with type 1 diabetes. Diabet Care 37(8): 2334 2342

15.

Skupien J, Warram JH, Niewczas MA et al (2014) Synergism between circulating tumor necrosis factor receptor 2 and HbA(1c) in determining renal decline during 5–18 years of follow-up in patients with type 1 diabetes and proteinuria. Diabet Care 37:2601–2608. https://doi.org/10.2337/dc13-1983CrossRef

16.

Krolewski AS, Niewczas MA, Skupien J et al (2014) Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria. Diabet Care 37:226–234. https://doi.org/10.2337/dc13-0985CrossRef

17.

Gohda T, Niewczas MA, Ficociello LH et al (2012) Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol 23:516–524. https://doi.org/10.1681/ASN.2011060628CrossRefPubMedPubMedCentral

18.

Pavkov ME, Weil EJ, Fufaa GD et al (2016) Tumor necrosis factor receptors 1 and 2 are associated with early glomerular lesions in type 2 diabetes. Kidney Int 89:226–234. https://doi.org/10.1038/ki.2015.278CrossRefPubMedPubMedCentral

19.

Heerspink HJL, Perco P, Mulder S et al (2019) Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia 62:1154–1166. https://doi.org/10.1007/s00125-019-4859-4CrossRefPubMedPubMedCentral

20.

Yamanouchi M, Skupien J, Niewczas MA et al (2017) Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end-stage renal disease. Kidney Int 92:258–266. https://doi.org/10.1016/j.kint.2017.02.010CrossRefPubMedPubMedCentral

21.

Hovind P, Rossing P, Tarnow L, Johnson RJ, Parving HH (2009) Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. Diabetes 58:1668–1671. https://doi.org/10.2337/db09-0014CrossRefPubMedPubMedCentral

22.

Jalal DI, Rivard CJ, Johnson RJ et al (2010) Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the coronary artery calcification in type 1 diabetes study. Nephrol Dial Transplant 25:1865–1969. https://doi.org/10.1093/ndt/gfp740CrossRefPubMedPubMedCentral

23.

Ficociello LH, Rosolowsky ET, Niewczas MA et al (2010) High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. Diabet Care 33:1337–1343. https://doi.org/10.2337/dc10-0227CrossRef

24.

Zoppini G, Targher G, Chonchol M et al (2012) Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabet Care 35:99–104. https://doi.org/10.2337/dc11-1346CrossRef

25.

De Cosmo S, Viazzi F, Pacilli A et al (2015) Serum uric acid and risk of CKD in type 2 diabetes. Clin J Am Soc Nephrol 10(11):1929. https://doi.org/10.2215/CJN.03140315CrossRef

26.

Ahola AJ, Sandholm N, Forsblom C, Harjutsalo V, Dahlström E, Groop PH (2017) The serum uric acid concentration is not causally linked to diabetic nephropathy in type 1 diabetes. Kidney Int 91(1178):1185. https://doi.org/10.1016/j.kint.2016.11.025CrossRef

27.

Pilemann-Lyberg S, Hansen TW, Tofte N et al (2019) Uric acid is an independent risk factor for decline in kidney function, cardiovascular events, and mortality in patients with type 1 diabetes. Diabet Care 42:1088–1094. https://doi.org/10.2337/dc18-2173CrossRef

28.

Doria A, Galecki AT, Spino C et al (2020) Serum urate lowering with allopurinol and kidney function in type 1 diabetes. N Engl J Med. https://doi.org/10.1056/NEJMoa1916624CrossRefPubMedPubMedCentral

29.

Velho G, Bouby N, Hadjadj S et al (2013) Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria. Diabet Care 36:3639–3645. https://doi.org/10.2337/dc13-0683CrossRef

30.

Velho G, Boustany RE, Lefèvre G et al (2016) Plasma copeptin, kidney outcomes, ischemic heart disease, and all-cause mortality in people with long-standing type 1 diabetes. Diabet Care 39:2288–2295. https://doi.org/10.2337/dc16-1003CrossRef

31.

Boertien WE, Riphagen IJ, Drion I et al (2013) Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33). Diabetologia 56:1680–1688. https://doi.org/10.1007/s00125-013-2922-0CrossRefPubMed

32.

Pikkemaat M, Melander O, Bengtsson Boströmd J (2015) Association between copeptin and declining glomerular filtration rate in people with newly diagnosed diabetes. The skaraborg diabetes register. J Diabet Complicat 29:1062–1065. https://doi.org/10.1016/j.jdiacomp.2015.07.006CrossRef

33.

Wannamethee SG, Welsh P, Lennon L, Papacosta O, Whincup PH, Sattar N (2016) Copeptin and the risk of incident stroke, CHD and cardiovascular mortality in older men with and without diabetes: The british regional Heart study. Diabetologia 59:1904–1912. https://doi.org/10.1007/s00125-016-4011-7CrossRefPubMedPubMedCentral

34.

Velho G, Ragot S, Boustany RE et al (2018) Plasma copeptin, kidney disease, and risk for cardiovascular morbidity and mortality in two cohorts of type 2 diabetes. Cardiovasc Diabetol 17:110. https://doi.org/10.1186/s12933-018-0753-5CrossRefPubMedPubMedCentral

35.

Sabbisetti VS, Waikar SS, Antoine DJ et al (2014) Blood kidney injury molecule-1 Is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. J Am Soc Nephrol 25:2177–2186. https://doi.org/10.1681/ASN.2013070758CrossRefPubMedPubMedCentral

36.

Nowak N, Skupien J, Niewczas MA et al (2016) Increased plasma kidney injury molecule-1 suggests early progressive renal decline in non-proteinuric patients with type 1 diabetes. Kidney Int 89:459–467. https://doi.org/10.1038/ki.2015.314CrossRefPubMedPubMedCentral

37.

Wu L, Li XQ, Chang DY et al (2020) Associations of urinary epidermal growth factor and monocyte chemotactic protein-1 with kidney involvement in patients with diabetic kidney disease. Nephrol Dial Transplant 35:291–297. https://doi.org/10.1093/ndt/gfy314CrossRefPubMed

38.

Satirapoj B, Dispan R, Radinahamed P, Kitiyakara C (2018) Urinary epidermal growth factor, monocyte chemoattractant protein-1 or their ratio as predictors for rapid loss of renal function in type 2 diabetic patients with diabetic kidney disease. BMC Nephrol. https://doi.org/10.1186/s12882-018-1043-xCrossRefPubMedPubMedCentral

39.

Nowak N, Skupien J, Smiles AM et al (2018) Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development. Kidney Int 93:1198–1206. https://doi.org/10.1016/j.kint.2017.11.024CrossRefPubMedPubMedCentral

40.

Mayer G, Heerspink HJL, Aschauer C et al (2017) Systems biology-derived biomarkers to predict progression of renal function decline in type 2 diabetes. Diabet Care. https://doi.org/10.2337/dc16-2202CrossRef

41.

Bjornstad P, Pyle L, Cherney DZI et al (2018) Plasma biomarkers improve prediction of diabetic kidney disease in adults with type 1 diabetes over a 12-year follow-up: CACTI study. Nephrol Dial Transplant 101(333):340. https://doi.org/10.1093/ndt/gfx255CrossRef

42.

Pezzolesi MG, Satake E, McDonnell KP, Major M, Smiles AM, Krolewski AS (2015) Circulating TGF-β1-regulated miRNAs and the risk of rapid progression to ESRD in type 1 diabetes. Diabetes 64:3285–3293. https://doi.org/10.2337/db15-0116CrossRefPubMedPubMedCentral

43.

Argyropoulos C, Wang K, Bernardo J et al (2015) Urinary microRNA profiling predicts the development of microalbuminuria in patients with type 1 diabetes. J Clin Med 4:1498–1517. https://doi.org/10.3390/jcm4071498CrossRefPubMedPubMedCentral

44.

Regmi A, Liu G, Zhong X et al (2019) Evaluation of Serum microRNAs in patients with diabetic kidney disease a nested case-controlled study and bioinformatics analysis. Med Sci Monit https://doi.org/10.12659/MSM.913265

45.

Assmann TS, Recamonde-Mendoza M, Costa AR et al (2019) Circulating miRNAs in diabetic kidney disease: case-control study and in silico analyses. Acta Diabetol 56:55–65. https://doi.org/10.1007/s00592-018-1216-xCrossRefPubMed

46.

Barutta F, Tricarico M, Corbelli A et al (2013) Urinary exosomal microRNAs in incipient diabetic nephropathy. PLoS One 8:e73798. https://doi.org/10.1371/journal.pone.0073798CrossRefPubMedPubMedCentral

47.

Uil M, Hau CM, Ahdi M et al (2019) Cellular origin and microRNA profiles of circulating extracellular vesicles in different stages of diabetic nephropathy. Clini Kidney J. https://doi.org/10.1093/ckj/sfz145CrossRef

48.

Prabu P, Rome S, Sathishkumar C et al (2019) MicroRNAs from urinary extracellular vesicles are non-invasive early biomarkers of diabetic nephropathy in type 2 diabetes patients with the Asian Indian phenotype. Diabet Metabolism. https://doi.org/10.1016/j.diabet.2018.08.004CrossRef

49.

Kim H, Bae YU, Jeon JS et al (2019) The circulating exosomal microRNAs related to albuminuria in patients with diabetic nephropathy. J Transl Med 17:236. https://doi.org/10.1186/s12967-019-1983-3CrossRefPubMedPubMedCentral

50.

Ghai V, Wu X, Bheda-Malge A et al (2018) Genome-wide profiling of urinary extracellular vesicle microRNAs associated with diabetic nephropathy in type 1 diabetes. Kidney Int Rep 3:555–572. https://doi.org/10.1016/j.ekir.2017.11.019CrossRefPubMed

51.

Good DM, Zürbig P, Argiles A et al (2010) Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteom 9(11):2424–2437CrossRef

52.

Roscioni SS, de Zeeuw D, Hellemons ME et al (2013) A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. Diabetologia. 56:259–267. https://doi.org/10.1007/s00125-012-2755-2CrossRefPubMed

53.

Zürbig P, Jerums G, Hovind P et al (2012) Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes 61:3304–3313. https://doi.org/10.2337/db12-0348CrossRefPubMedPubMedCentral

54.

Lindhardt M, Persson F, Zürbig P et al (2017) Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study. Nephrol Dial Transplant 32:1866–1873. https://doi.org/10.1093/ndt/gfw292CrossRefPubMed

55.

Schanstra JP, Zurbig P, Alkhalaf A et al (2015) Diagnosis and prediction of CKD progression by assessment of urinary peptides. J Am Soc Nephrol 26:1999–2010. https://doi.org/10.1681/ASN.2014050423CrossRefPubMedPubMedCentral

56.

Pontillo C, Jacobs L, Staessen JA et al (2017) A urinary proteome-based classifier for the early detection of decline in glomerular filtration. Nephrol Dial Transpl 32:1510–1516. https://doi.org/10.1093/ndt/gfw239CrossRef

57.

Zurbig P, Mischak H, Menne J, Haller H (2019) CKD273 enables efficient prediction of diabetic nephropathy in nonalbuminuric patients. DIABET Care 42:e4–e5. https://doi.org/10.2337/dc18-1322CrossRef

58.

Tofte N, Lindhardt M, Adamova K et al (2020) Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. Lancet Diabet Endocrinol 8:301–312. https://doi.org/10.1016/S2213-8587(20)30026-7CrossRef

59.

Siwy J, Klein T, Rosler M, von Eynatten M (2019) Urinary proteomics as a tool to identify kidney responders to dipeptidyl peptidase-4 Inhibition a hypothesis-generating analysis from the MARLINA-T2D Trial. PROTEOMICS-Clin Appl. https://doi.org/10.1002/prca.201800144CrossRefPubMed

60.

Niewczas MA, Pavkov ME, Skupien J et al (2019) A signature of circulating inflammatory proteins and development of end stage renal disease in diabetes. Nat Med. https://doi.org/10.1038/s41591-019-0415-5CrossRefPubMedPubMedCentral

61.

Hocher B, Adamski J (2017) Metabolomics for clinical use and research in chronic kidney disease. Nat Rev Nephrol 13:269–284. https://doi.org/10.1038/nrneph.2017.30CrossRefPubMed

62.

Niewczas MA, Mathew AV, Croall S et al (2017) Circulating modified metabolites and a risk of ESRD in patients with type 1 diabetes and chronic kidney disease. Diabet Care 40:383–390. https://doi.org/10.2337/dc16-0173CrossRef

63.

Tofte N, Suvitaival T, Trost K et al (2019) Metabolomic assessment reveals alteration in polyols and branched chain amino acids associated with present and future renal impairment in a discovery cohort of 637 persons with type 1 diabetes. Front Endocrinol (Lausanne). https://doi.org/10.3389/fendo.2019.00818CrossRef

64.

Tofte N, Suvitaival T, Ahonen L et al (2019) Lipidomic analysis reveals sphingomyelin and phosphatidylcholine species associated with renal impairment and all-cause mortality in type 1 diabetes. Sci Rep 9:16398. https://doi.org/10.1038/s41598-019-52916-wCrossRefPubMedPubMedCentral

65.

Solini A, Manca ML, Penno G, Pugliese G, Cobb JE, Ferrannini E (2016) Prediction of declining renal function and albuminuria in patients with type 2 diabetes by metabolomics. J Clin Endocrinol Metab 101(2):696–704CrossRefPubMed

66.

Afshinnia F, Nair V, Lin J et al (2019) Increased lipogenesis and impaired β-oxidation predict type 2 diabetic kidney disease progression in American Indians. JCI insight 4:e130317. https://doi.org/10.1172/jci.insight.130317CrossRefPubMedCentral

67.

Krolewski AS (2015) Progressive renal decline: the new paradigm of diabetic nephropathy in type 1 diabetes. Diabet Care 38:954–962. https://doi.org/10.2337/dc15-0184CrossRef

68.

Porrini E, Ruggenenti P, Luis-Lima S et al (2019) Estimated GFR: time for a critical appraisal. Nat Rev Nephrol 15:177–190. https://doi.org/10.1038/s41581-018-0080-9CrossRefPubMed

69.

Inker LA, Mondal H, Greene T et al (2016) Early change in urine protein as a surrogate end point in studies of IgA nephropathy: an individual-patient meta-analysis. Am J Kidney Dis 68:392–401. https://doi.org/10.1053/j.ajkd.2016.02.042CrossRefPubMed

70.

Holtkamp FA, de Zeeuw D, Thomas MC et al (2011) An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 80:282–287. https://doi.org/10.1038/ki.2011.79CrossRefPubMed

71.

Mora-Gutiérrez MJ, Garcia-Fernandez N, Roblero MFS et al (2017) Arterial spin labeling MRI is able to detect early hemodynamic changes in diabetic nephropathy. J Magn Reson Imaging. https://doi.org/10.1002/jmri.25717CrossRefPubMed

72.

Wang YC, Feng Y, Lu CQ, Ju S (2018) Renal fat fraction and diffusion tensor imaging in patients with early-stage diabetic nephropathy. Eur Radiol 28:3326–3334. https://doi.org/10.1007/s00330-017-5298-6CrossRefPubMed

73.

Inoue T, Kozawa E, Okada H et al (2011) Noninvasive evaluation of kidney hypoxia and fibrosis using magnetic resonance imaging. J Am Soc Nephrol 22:1429–1434. https://doi.org/10.1681/ASN.2010111143CrossRefPubMedPubMedCentral

74.

Michaely HJ, Metzger L, Haneder S, Hansmann J, Schoenberg SO, Attenberger UI (2012) Renal BOLD-MRI does not reflect renal function in chronic kidney disease. Kidney Int 81:684–689. https://doi.org/10.1038/ki.2011.455CrossRefPubMed

Titel: Novel biomarkers of diabetic kidney disease: current status and potential clinical application
verfasst von: Federica Barutta
Stefania Bellini
Silvia Canepa
Marilena Durazzo
Gabriella Gruden
Publikationsdatum: 02.02.2021
Verlag: Springer Milan
Erschienen in: Acta Diabetologica / Ausgabe 7/2021
Print ISSN: 0940-5429
Elektronische ISSN: 1432-5233
DOI: https://doi.org/10.1007/s00592-020-01656-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2021

The triumvirate: why hypertension, obesity, and diabetes are risk factors for adverse effects in patients with COVID-19

Impact of lockdown during COVID-19 emergency on glucose metrics of children and adolescents with type 1 diabetes in Piedmont, Italy

Sodium–glucose cotransporter 2 inhibitors as an add-on therapy to insulin for type 1 diabetes mellitus: Meta-analysis of randomized controlled trials

Vascular complications of diabetes: natural history and corresponding risks of dementia in a national cohort of adults with diabetes

The interaction between metabolic syndrome and physical activity, and risk for gestational diabetes mellitus